Ilex/Millennium Campath
Executive Summary
Phase II multiple sclerosis and kidney transplant clinical trials are being evaluated for 2001, but plans have not been set. At UBS Warburg conference, Ilex Oncology CEO Richard Love incorrectly indicated the drug would be entering Phase III for kidney transplants and MS (1"The Pink Sheet" Oct. 9, p. 23)